The week in review

Warnings on ongoing medication shortages and substandard products, a call for action on expanding scope of practice and for regulators to proactively focus on risks were among the hot topics this week Multiple medications used to treat attention deficit hyperactivity disorder (ADHD) are likely to remain in short supply until 2026, the Therapeutic Goods Administration